PPBT ▲ +18.5% - Purple Biotech Ltd $PPBT - New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies Purple Biotech shares rose 18.5% following the allowance of a new U.S. patent that strengthens intellectual property protection for its CAPTN-3 modular platform, a technology designed for developing next-generation multispecific antibodies. The patent allowance reduces development risk and extends the company's competitive moat around a core therapeutic platform, which typically drives investor confidence in biotech firms with early-stage technology portfolios. 02-SEP-2026 07:30 AM ET